# Ginseng: ginsenosides, neuroplasticity and clinical evidence limits

- Canonical: https://nutrifit.health/knowledge/panax-ginseng-ginsenosides-neuroplasticity
- Language: en
- Published: 2026-10-03T18:30:03.884Z
- Updated: 2026-10-03T18:30:03.884Z
- Author: NutriFit Editorial

> Panax ginseng chemistry and processing, intestinal metabolism, BDNF/TrkB, receptors, microglia and stress pathways, with clinical trials and practical limitations.

Ginseng is interesting to neurobiology because its constituents affect several levels of nervous-tissue function: metabolite formation in the gut, receptor signalling, astrocyte and microglial states, neurotrophic-factor expression and cellular responses to stress. This breadth also creates the main difficulty. A change in a protein in culture, improved behaviour in a mouse and reduced fatigue in a person are different findings, and the causal links between them must be established. For an oral preparation, this chain begins before the brain: with botanical identity, extract composition, microbial metabolism and actual exposure.

In this article, Panax ginseng means Asian ginseng, including Korean material. American Panax quinquefolius and Panax notoginseng are considered separately when necessary to understand a study. “Indian ginseng” refers to ashwagandha and does not make it a member of Panax. “Adaptogen” describes a historical research concept of resistance to challenges; it does not replace a specific indication, clinical endpoint or safety assessment.

## From the root to active molecules

### The dammarane scaffold and sugar chains

The main ginsenosides are triterpenoid saponins. In many, the hydrophobic portion consists of four fused rings of a dammarane scaffold, while the hydrophilic portion consists of sugars attached through oxygen. Sugar number, glycosidic-bond position and stereocentre configuration influence solubility, membrane interactions, enzymatic conversion and receptor effects. Total saponin content therefore does not reveal a preparation’s complete pharmacological profile.

The two main series are called protopanaxadiol, PPD, and protopanaxatriol, PPT, derivatives. These historical names should not be read as a literal count of all hydroxyl groups: the relevant PPD aglycone has hydroxyls at C3, C12 and C20, and PPT has an additional hydroxyl at C6. The 20(S) configuration matters for common natural representatives; some processing products also have 20(R) epimers. The aglycone side chain contains a C24=C25 double bond. This is not a C25=C26 bond, nor stereochemistry newly created by a schematic drawing.

| Chemical series | Typical representatives | Characteristic sugar-chain positions | Interpretive point |
|---|---|---|---|
| PPD | Rb1, Rb2, Rc, Rd, Rg3, Rh2, F2, compound K | C3 and C20 in many starting compounds; some sugars are removed during conversion | Different members can affect the same receptor differently |
| PPT | Rg1, Re, Rf, Rg2, Rh1 | Often C6 and/or C20; the exact structure is compound-specific | The extra hydroxyl and different sugars alter molecular properties |
| Oleanane series | Ro | A pentacyclic oleanolic-acid aglycone with its own glycosylated structure | Ro should not be drawn as another PPD/PPT epimer |

Rb1 has four glucose residues: one disaccharide chain at C3 and another at C20. Rd retains the C3 disaccharide and one glucose at C20; F2 has one at each position. Compound K, also called CK or IH-901, is 20-O-β-D-glucopyranosyl-20(S)-PPD: its sole glucose is attached at C20, with a free hydroxyl at C3. Its formula is C₃₆H₆₂O₈. Rh2 has the same molecular formula but its sugar is at C3, so these molecules cannot be equated by mass or sugar count.

### White, red and fermented ginseng

White ginseng is produced by drying the root; red ginseng by steaming followed by drying. Temperature, duration, moisture and acidity determine the chemical changes; one fixed procedure cannot describe all products. Research compares traditional processing near water’s boiling point with higher-temperature technological variants. Results apply to the process and material actually studied.

Heating may cause successive sugar loss, C20 epimerisation and dehydration. In the PPD series, the route from Rb1 through Rd to Rg3 involves removing sugars at C20. Rg3 retains two sugars at C3; removing another gives Rh2. This is glycosidic-bond hydrolysis, not loss of water from the aglycone. Rg3 dehydration produces other compounds, including Rk1 and Rg5, with different positions of the new double bond near C20. Epimerisation between 20(S) and 20(R) changes one centre; it does not turn the whole product into a racemic mixture.

Rs3, whose sugar chain contains an acetyl group, has also been identified in red ginseng. It cannot be placed on the same reaction arrow as a simple Rg3 dehydration product: an acetyl substituent requires a different chemical history. These distinctions help when reading chromatograms or certificates of analysis. They do not prove that a red, heavily heated or rare-saponin-enriched product automatically works better in the human brain.

[![Fresh ginseng roots, steam processing, and separate samples of dried white and red ginseng root.](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-pg-root-processing.png)](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-pg-root-processing.png)

### Microbiota as part of pharmacokinetics

After oral intake, starting glycosides may undergo hydrolysis by intestinal microorganisms. The sequence Rb1 → Rd → F2 → CK is well studied: three glucose residues are removed stepwise. Its overall chemical balance can be written Rb1 + 3H₂O → CK + 3 glucose molecules. This describes the hydrolysis balance, not one reaction catalysed by one enzyme. Each step requires suitable glycosidase activity, and intermediates may accumulate.

Alternative routes pass through gypenoside XVII and then F2 or gypenoside LXXV. These have been detected during incubation with human gut microbiota; assignment of particular intermediate peaks may be less certain than identification against a standard. Conversion rate and dominant route differ between samples. Microbiota can therefore alter exposure, but this does not mean everyone with a low response needs a probiotic.

Strain specificity matters in practice. In a study of Bifidobacterium lactis Bi-07 and Lactobacillus rhamnosus HN001, both strains converted starting PPD glycosides, but the final profiles differed: one converted Rd further to F2, while the other predominantly stopped at Rd. Current bacterial genus names may differ from those in the publication, but strain identity remains essential. Manufacturing-fermentation data do not prove that any lactobacillus capsule increases CK formation in a patient.

Removing sugars often improves a metabolite’s ability to interact with membranes, but does not abolish absorption barriers. In transport-cell systems and animal models, CK was a substrate of P-glycoprotein, ABCB1, which can return it towards the intestinal lumen. Increased absorption after experimentally inhibiting this transporter is not a reason to combine ginseng with verapamil or cyclosporine. These drugs have their own effects and risks, and greater plasma exposure does not establish greater therapeutic benefit.

In healthy-volunteer studies, fermented or CK-enriched preparations produced substantially greater plasma CK exposure than the particular red-ginseng comparator. In one CK-30 comparison, the Cmax ratio was approximately 118 and the AUClast ratio approximately 135; in another comparison of fermented and unfermented red ginseng, the respective ratios were approximately 69 and 75. These are results for different formulations and study conditions, not universal bioavailability multipliers for any “fermented ginseng”. They did not measure depression-treatment efficacy or human neurogenesis either.

Cmax is the maximum measured concentration, Tmax the time at which it occurs, and AUC the area under the concentration–time curve, describing systemic exposure. Under comparable conditions, absolute bioavailability F is estimated as F = (AUCₒᵣₐₗ / Doseₒᵣₐₗ) / (AUCᵢᵥ / Doseᵢᵥ). This requires an intravenous comparison, comparable dosing conditions and consideration of pharmacokinetic linearity. A plasma AUC after an oral extract alone does not provide absolute F, brain concentration or clearance rate.

The blood–brain barrier needs separate consideration. In a preclinical study, Rb1 crossed a model of rat brain endothelial cells; GLUT1-inhibition findings supported involvement of that transporter. This challenges the categorical claim that starting glycosides cannot reach the brain at all, but does not establish a single human transport mechanism. Nor can CK be promised unrestricted passage through the barrier: transporters, protein binding, metabolism and free concentration at the relevant target remain important questions.

## Neurogenesis and plasticity: what an experiment actually measures

### The subgranular zone and cell fate

In the rodent hippocampal dentate gyrus, neural stem cells in the subgranular zone, SGZ, produce intermediate proliferating cells, neuroblasts and immature granule neurons. Radial type-1 cells often express Sox2 and GFAP; later stages are assessed with proliferation and neuronal-differentiation markers. DCX is associated with immature neurons, NeuN predominantly with more mature neuronal identity. This is maturation within a cellular niche, not instantaneous conversion of every GFAP-positive astrocyte into a new functional neuron.

In chronic mild-stress experiments, Rg1 altered mouse behaviour and measures of BDNF, neurogenesis and dendritic spines. D-galactose-injury models investigated neural-stem-cell viability, proliferation and p53/p21 signalling. When interpreting such work, recovery from experimental injury must be distinguished from enhancement of normal healthy-tissue function. Reduced cellular senescence in culture does not mean demonstrated rejuvenation of the human hippocampus.

BrdU and other DNA-synthesis labels show that a cell passed through the relevant cell-cycle stage. They do not automatically establish its final fate, survival or integration into a neural network. A neurogenesis conclusion requires combined markers, temporal tracking, morphology and ideally functional integration. Increased Tuj1 or MAP2 supports neuronal differentiation, but simultaneous changes in GFAP or oligodendrocyte markers may involve several cell lineages. Rg1’s overall effect therefore cannot be described as obligatory selective differentiation only into neurons.

The p53/p21 pathway can restrict the cell cycle in response to injury. Its change in a particular NSC model is interesting, but transferring CDK2/CDK4 findings from haematopoietic stem cells to neural cells requires separate evidence. Promoting proliferation is not an unconditionally beneficial goal either: genomic stability, correct differentiation and the microenvironment must be preserved.

Several kinds of evidence now support adult human neurogenesis, although methods and functional interpretation remain debated. A postmortem hippocampal study analysing hundreds of thousands of cell nuclei identified molecular profiles of stem cells, neuroblasts and immature granule neurons, with differences in ageing and Alzheimer’s disease. These findings concern human tissue, not a ginseng trial. There is still no basis for claiming that ordinary oral Panax ginseng demonstrably increases the birth of functional neurons in humans.

[![A dendritic branch with mushroom-shaped spines and contacting axonal boutons; vesicles and the gap between membranes are visible at the nearest synapse.](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-pg-plasticity-landscape.png)](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-pg-plasticity-landscape.png)

### cAMP, CREB and BDNF/TrkB

One investigated pathway links intracellular signalling to neurotrophic-factor expression. Adenylyl cyclase catalyses ATP → cAMP + PPi, where PPi is pyrophosphate. Increased cAMP can activate protein kinase A, PKA; its catalytic subunits participate in CREB phosphorylation, including at Ser133. With coactivators and other signals, CREB regulates transcription of genes associated with survival and plasticity. Phosphorylation at one position does not guarantee activation of every dependent gene.

BDNF has different regulatory promoters and transcripts, including the frequently studied promoter IV and shared coding region IX. Differences in promoter activity help explain why neuronal activity, stress and pharmacological interventions produce different responses. Measuring cAMP, pCREB or BDNF after Rg1 nevertheless does not establish direct Rg1 binding to adenylyl cyclase. For example, retinal-ganglion-cell neurite work supported cAMP/PKA/CREB involvement, but a retinal model is not equivalent to the whole human hippocampus.

BDNF is synthesised as a precursor, processed and secreted. Mature BDNF binds full-length TrkB at the membrane; receptor dimerisation and phosphorylation initiate several branches. Shc/FRS2-associated signals lead to Ras–MAPK/ERK and PI3K–Akt, while another docking region recruits PLCγ. Tyrosine-residue numbering depends on species and sequence, so without that context, numbers should not become universal receptor addresses.

The PI3K–Akt branch affects cell survival and regulation of Bcl-2-family proteins. Bad phosphorylation can reduce its proapoptotic action; Bax behaviour, cytochrome-c release and mitochondrial apoptosis depend on the wider network. PLCγ cleaves PIP₂ into IP₃ and DAG: IP₃ promotes Ca²⁺ release from the endoplasmic reticulum, while DAG contributes to PKC activation. Through Ca²⁺/calmodulin and CaMKII, synaptic properties change, including AMPA-receptor phosphorylation and trafficking. This regulated network cannot be replaced by a linear promise that “more BDNF always means better memory”.

In an APP/PS1-related transgenic mouse model, investigators assessed BDNF/TrkB, synaptic proteins and long-term potentiation, LTP, after Rg1. LTP is a sustained change in transmission efficacy following a defined stimulation protocol, useful for studying learning mechanisms. It is not a direct measure of a patient’s everyday memory and does not demonstrate Alzheimer’s treatment. Clinical conclusions require independent trials with patient-relevant outcomes.

### Synaptic proteins and dendritic spines

Molecular measures become clearer when related to contact architecture. Synaptophysin is present in synaptic-vesicle membranes and is commonly used as a presynaptic marker. PSD-95 forms a protein scaffold at the postsynaptic density; its PDZ domains organise receptor and signalling complexes. PSD-95 association with AMPA receptors is often mediated by auxiliary proteins, including TARPs, so it should not always be drawn as direct binding to GluA1.

| Component | Location and function | Meaning of the measurement |
|---|---|---|
| Synaptophysin, SYP | Presynaptic-vesicle membrane; organisation of vesicular machinery | A content change supports a hypothesis of presynaptic change, not a count of functioning synapses |
| PSD-95, DLG4 | Postsynaptic density; protein-complex organisation through PDZ domains | Scaffold changes need comparison with morphology and transmission |
| Syntaxin-1 and SNAP-25 | Presynaptic membrane; SNARE components | Together with vesicular synaptobrevin/VAMP, they support vesicle fusion; two proteins do not make the full complex |
| AMPA receptors, including GluA1 | Postsynaptic membrane | Receptor number, phosphorylation and trafficking influence transmission, but one protein measure does not describe the whole synapse |

Dendritic spines increase surface area and organise local signalling spaces. A mushroom-shaped spine typically has a narrow neck and enlarged head, but shape is dynamic and does not provide an absolute classification of memory quality. Golgi–Cox staining helps assess spine morphology and density; it does not automatically show that every contact functions. Restoration of density after stress should be described with its model context, not as universal construction of “new neural connections” in a person taking a supplement.

## Receptors and synaptic support: different ginsenosides have different effects

### NMDA receptors and astrocytic glutamate uptake

NMDA receptors conduct cations, including Ca²⁺, and contribute to normal plasticity. Opening requires glutamate, a coagonist—glycine or D-serine—and a membrane potential permitting relief of the Mg²⁺ block. Excessive, prolonged activation can produce a calcium load associated with calpain activation, mitochondrial dysfunction and cell injury. Reducing pathological activation and suppressing normal transmission are therefore different aims: “blocking NMDA” does not automatically improve memory.

In cultured rat hippocampal neurons, Rg3 reduced NMDA-dependent responses; pharmacological findings suggested involvement of the glycine-modulatory site. A separate Rh2 experiment supported interaction with the polyamine site. These findings cannot be reduced to one site of action for all ginsenosides or taken as evidence of competitive glutamate displacement. Experimental blockers help locate a mechanism in the system studied, but do not determine the effective free concentration after ordinary human root intake.

Synaptic glutamate exposure also depends on astrocytes. Their EAAT2 transporter, called GLT-1 in rodents, removes extracellular glutamate using ion gradients. Glutamine synthetase then converts it into glutamine. A simplified energetic balance is glutamate + NH₄⁺ + ATP → glutamine + ADP + Pi; the acid–base balance of all solution species is not expanded here. Glutamine can return to neurons for use in the glutamate–glutamine cycle. This support of transmission differs from directly modifying the NMDA receptor.

In an MPTP mouse model, Rb1 increased GLT-1 measures through a mechanism involving increased NF-κB nuclear translocation. Rd studies in astrocyte cultures and a rat ischaemia model examined PI3K–Akt- and ERK-dependent transport regulation. These results matter when interpreting an overall diagram: NF-κB is not exclusively a “bad inflammatory switch” that should be turned off in every cell. Its function depends on cell type, timing and target genes. Improved uptake in a model does not establish stroke prevention or neurodegenerative-disease treatment by any extract.

### GABA_A: the effect’s direction cannot be assigned to the entire class

GABA_A is a ligand-gated channel carrying predominantly Cl⁻ and also HCO₃⁻. Its cellular effect depends on electrochemical gradients, resting potential, reversal potential and conductance changes. Current can be described by I = g(Vₘ − Eᵣₑᵥ): its direction and magnitude depend on more than the number of open channels. Depolarisation does not necessarily mean excitation; increased conductance can weaken other inputs through shunting.

In a recombinant system, CK and PPT inhibited GABA-induced currents. Other ginsenosides and models produced different profiles; experimental epilepsy work described CK-related GABA transmission changes requiring a more complex interpretation. CK therefore cannot be labelled a universal positive allosteric modulator, nor can that label be extended to all ginseng. Molecule, receptor-subunit composition, concentration and tissue state differ.

Flumazenil blocks the benzodiazepine site of GABA_A. A behavioural change—or its absence—after flumazenil does not itself prove direct ginsenoside binding at a particular channel site or establish absence of tolerance. For professionals, the practical relevance is caution in interpreting insomnia, sedation and combinations with psychotropic drugs. Receptor experiments do not justify replacing prescribed treatment with ginseng’s “natural GABA modulation”.

## Microglia and amyloid: cellular mechanisms with limited clinical transfer

### Inflammatory signalling and microglial states

Microglia support nervous tissue, remove cellular debris and respond to infectious and damage signals. The familiar M0 → M1 or M2 sequence is convenient for an introduction, but inadequately describes the diversity of states in the living brain. iNOS, CD16 and CD86 are associated with particular inflammatory programmes; Arg1, CD206, IL-10 and other measures can accompany alternative responses. Combinations change over time, and one marker does not define a cell’s whole function. Ym1 is particularly associated with mouse models, not a universal human indicator of “restorative microglia”.

In an LPS mouse model, Rg1 reduced some inflammatory measures and increased certain alternative-state markers. BV2 and primary-microglia work linked responses to GPER and downstream NF-κB/MAPK signals. Increased IL-10, TGF-β or IGF-1, where demonstrated in a particular model, must be interpreted in context: these molecules do not identify an unconditionally beneficial state at every disease stage. Suppressing protective immune responses can also be undesirable.

The classical LPS-dependent pathway begins at the membrane TLR4/MD-2 complex. Through adaptors and mediators including MyD88, IRAK, TRAF6 and TAK1, the signal reaches IKK. IκB phosphorylation and subsequent removal release NF-κB for nuclear translocation and transcriptional regulation. MAPK branches can operate in parallel; a drawing of one branch should not imply that the entire response follows a single line.

Primary Rb1/CK work used peritoneal macrophages and a mouse intestinal-inflammation model. IRAK-1 activation was inhibited, whereas LPS–TLR4 interaction and particular other IRAKs did not show the same inhibition. It is therefore incorrect to depict Rb1/CK as proven universal blockers of LPS binding to TLR4/MD-2 in human microglia. The study supports a specific mechanism in a specific system, not broad clinical “neuroprotection” by any extract.

### Aβ cleavage and cellular clearance

Amyloid peptides arise through proteolytic APP processing; their concentrations reflect production, aggregation, transport and degradation. Neprilysin, NEP, is one enzyme capable of cleaving Aβ. In a cell model with modified APP, Rg3 was followed by increased NEP and reduced Aβ₄₀/Aβ₄₂. This supports a clearance hypothesis but does not mean all aggregates become “safe monomers”: proteolysis produces peptide fragments, whose subsequent fate depends on the system.

Microglia provide another route: recognition, uptake and intracellular processing. In primary microglial cultures, Rg3 increased Aβ uptake measures and expression of class-A scavenger receptor MSR-A/SR-A. This receptor should not be confused with methionine sulfoxide reductase MSRA, a different protein with a similar abbreviation. Later HMO6 and animal work also examined endocytosis, caveolin/clathrin, p38/ERK and NEP/IDE. Intracellular proteolysis and lysosomal disposal involve several compartments; putting every enzyme in one schematic vesicle cannot establish a universal route.

Aβ changes in culture, enhanced cell uptake and the clinical course of Alzheimer’s disease are separate evidence levels. Phagocytosis can depend on Aβ form, inflammatory state, age and the ability to complete disposal. Treatment claims require clinical cognitive and functional outcomes, not merely an attractive amyloid-removal mechanism.

## Stress systems: where established ginseng mechanisms end

### Hypothalamus, pituitary, adrenal gland and feedback

In the hypothalamic–pituitary–adrenal axis, hypothalamic CRH acts at CRHR1 on pituitary corticotrophs, triggering ACTH secretion. ACTH acts through adrenal-cortex MC2R to support glucocorticoid synthesis. Cortisol is the principal hormone in this human description; many rodent models measure corticosterone. Glucocorticoid receptors, GR, provide feedback at several levels. Circadian rhythms, pulsatile secretion, tissue sensitivity and sampling time matter; one morning value does not describe the entire system.

In a cell experiment, Rg1 interacted with a GR-dependent response at micromolar concentrations, with activity substantially different from dexamethasone. Antagonist blockade helped confirm receptor involvement in that system. Mouse stress models also showed Rg1-associated corticosterone and behavioural changes. This allows discussion of stress-signalling links, but does not establish a clinical mechanism of bidirectional hormonal “normalisation” after human ginseng use.

Fatigue and burnout do not automatically imply cortisol deficiency, and “adrenal fatigue” does not substitute for diagnosis of endocrine disease. Suspected adrenal insufficiency or hypercortisolism requires accepted diagnostic approaches. Ginseng cannot be prescribed as something that simultaneously raises low and lowers high cortisol regardless of cause. Experimental changes should remain mechanistic observations identified by species and conditions.

### Hsp70, protein folding and apoptosis

Hsp70-family proteins help maintain proteostasis: they bind exposed hydrophobic polypeptide regions and reduce inappropriate interactions. Their working cycle requires ATP. In the ATP-bound state, substrate exchange is more dynamic; ATP hydrolysis to ADP and Pi, regulated by cochaperones, favours stable binding. Nucleotide-exchange factors help remove ADP, bind fresh ATP and release the substrate for another cycle. This is not instantaneous “repair” of every damaged protein.

Heat and other cellular stresses can activate HSF1 and expression of genes including HSPA1A/HSPA1B. Some model studies link Hsp70 to restricted apoptosis. Apaf-1 experiments described both interference with particular apoptosome-assembly stages and impaired procaspase-9 recruitment without identical effects on overall oligomerisation. The downstream caspase cascade then changes. JNK relationships are also context-dependent, so one inhibitory sign should not suggest universal suppression of apoptosis or every stress kinase.

An important study underlying the original “adaptogenic Hsp70 effect” concerned ADAPT-232, a mixture of rhodiola, eleutherococcus and schisandra, not Panax ginseng. It assessed mice and peripheral Hsp72, not demonstrated Hsp70 elevation in the human brain after ginseng. Chaperone biology remains scientifically valuable, but this study does not establish “ginseng → Hsp70 → prevention of neurodegeneration”. General cell biology and unconfirmed attribution to the plant must remain clearly distinguished.

## What was measured in humans

### Cognitive tasks and mental fatigue

Small crossover trials of standardised G115 extract in healthy young adults examined task speed and accuracy, attention, mood and subjective fatigue. One included 30 people receiving 200 or 400 mg; particular changes in serial subtraction and fatigue emerged after load. The ten-minute block included several tasks, not just continuous subtraction of sevens. Blood-glucose changes accompanied some findings but did not prove improved brain energy supply.

Another experiment with 20 participants compared 200, 400 and 600 mg. The most favourable result for certain memory measures did not follow a simple linear dose relationship; some attention-speed and alertness measures worsened. These studies therefore cannot identify a universal “optimal nootropic dose” for every extract. Composition, task, sampling time, multiple comparisons and small sample sizes limit transfer.

Repeated dosing assessed on days one and eight did not show a simple progressive benefit or universal loss of effect. Different doses affected mood and arithmetic tasks differently. Lack of additional gain in that short design does not demonstrate receptor tolerance or justify “five days on, two days off”.

### Fatigue, MCI and a vascular example involving another species

A four-week study involved 90 people with idiopathic chronic fatigue, not diagnosed ME/CFS. A particular Panax ginseng extract at 1 or 2 g daily was compared with placebo; 88 completed the study. The between-group result for the overall primary NRS measure did not reach the accepted significance threshold: P = 0.068. There were signals in particular fatigue components, and a VAS advantage in the 2-g group. The trial cannot be described as unequivocally positive for all principal outcomes.

Some oxidative-stress measures decreased and glutathione-system components changed. SOD and catalase activity did not show the increase claimed in the original article. Biochemical results do not replace well-being, function or the primary endpoint. One participant receiving 2 g developed a rash and withdrew; this does not determine risk frequency for every product, but should remain in the safety description.

In mild cognitive impairment, MCI, ginseng powder at 3 g was studied over six months. Among 90 participants, particular immediate and delayed complex-figure recall measures changed. This is a limited signal in specific tests, not established dementia prevention. An eight-week study in 51 healthy volunteers compared Korean red ginseng with placebo using cognitive measures and MRI morphometry. A regional MRI-volume change is not a count of new neurons and does not directly confirm neurogenesis.

The large post-ischaemic-stroke Xuesaitong trial should be retained with correct species and product attribution. It studied Panax notoginseng saponins, not ordinary Panax ginseng root. Across 67 centres, 3,072 patients were randomised; the modified intention-to-treat analysis included 2,966. Functional independence, mRS 0–2, at three months was 89.3% versus 82.4%; the odds ratio was 1.95, with a 95% confidence interval of 1.56–2.44. This concerned a particular adjunctive treatment in a defined post-stroke population, not stroke prevention with a supplement. Similar serious-adverse-event frequencies do not demonstrate absolute safety.

| Material and population studied | Outcomes assessed | Main limit |
|---|---|---|
| G115; small samples of healthy young adults | Attention, memory, serial subtraction, mood and post-load fatigue | Selective short-term effects and variable dose relationships; not cognitive-disease treatment |
| Particular P. ginseng extract; 90 people with idiopathic fatigue | Four-week NRS/VAS and biochemical measures | Overall primary NRS P = 0.068; positive individual outcomes do not make the whole trial positive |
| P. ginseng powder; 90 participants with MCI | Six-month cognitive tests | A signal in particular recall tasks, not established dementia prevention |
| Korean red ginseng; 51 healthy participants | Eight-week cognitive measures and MRI | Small study; MRI volume is not neurogenesis |
| P. notoginseng saponins/Xuesaitong after ischaemic stroke | mRS 0–2 at three months | Another species and a particular clinical setting; cannot be transferred to P. ginseng supplements |

## Applying this knowledge professionally

### First identify the material and clinical question

A useful assessment starts with species, plant part, technology and composition. Root powder, standardised extract, red ginseng, fermented product and isolated ginsenoside must be distinguished. Extractant, drug-to-extract ratio, marker content and individual-ginsenoside profile matter when matching a study. “Ginseng” on a label, or just a percentage of “total saponins”, is insufficient to transfer G115, CK-30 or Xuesaitong findings.

Calculating marker quantity helps interpret a label: marker amount = extract mass × mass fraction. For example, 200 mg × 0.04 = 8 mg. This is an arithmetic example for an extract containing 4% markers, not a universal treatment dose or the equivalent of 8 mg Rg1 or CK. Identical totals can conceal different distributions of Rb1, Rg1 and rare processing products. Different markers or analytical methods in a certificate also change comparability.

| Product question | Purpose |
|---|---|
| Which species and plant part? | Exclude substitution with American ginseng, notoginseng or ashwagandha |
| Powder, extract or isolated compound? | Avoid transferring doses and pharmacokinetics between materials |
| How is composition standardised? | Match markers and profile to the studied preparation |
| Is the batch traceable and analysed for contaminants? | Assess quality, contamination and composition reliability |
| Which outcome is expected, and when will it be assessed? | Avoid treating a cellular marker change as a clinical goal |

Fatigue warrants assessment of sleep, workload, nutrition, anaemia, endocrine disorders, medication effects, depression and other possibilities according to history. New cognitive complaints require attention to duration, daily-function impairment, neurological signs and medicines. A supplement should not delay diagnosis. Normal forgetfulness after sleep deprivation, MCI and dementia are different populations; a student serial-subtraction experiment does not establish treatment for all three.

Where discussion of a particular adult product is appropriate, the outcome should be defined in advance: for example, subjective fatigue alongside functioning, sleep, tolerability and a fixed decision-review time. Assessment conditions should remain similar, with expectations, workload changes and concurrent treatment considered. No established algorithm uses blood BDNF, a commercial microbiome test or a single cortisol value to select a “neuroplastic” ginseng dose. Antibiotics, probiotics or ABCB1 inhibitors should not be prescribed to increase CK on the basis of experimental pathways.

### Safety and drug combinations

The European regulatory description of ginseng root concerns traditional use for asthenic symptoms such as fatigue and weakness. Traditional-use status differs from demonstrated neurodegenerative-disease treatment. Gastrointestinal symptoms, sleep disturbance and hypersensitivity can occur. Evidence is insufficient in children, pregnancy and lactation; rat-embryo culture findings cannot calculate a safe human concentration. Without such a boundary, independent use should not be proposed for these groups.

Interactions cannot be described by one list of “immune stimulation plus blood thinning”. Warfarin findings differed by species and product: American ginseng reduced anticoagulant effect in a controlled experiment, whereas a small short Asian-ginseng study did not find that result. This does not guarantee safety of every product, but highlights coordination during narrow-therapeutic-range treatment and clinician-directed monitoring. Findings cannot automatically be extended to all direct oral anticoagulants.

In healthy volunteers, one Panax ginseng preparation reduced midazolam exposure, supporting possible change in CYP3A-mediated metabolism; other designs gave different results. Cyclosporine, tacrolimus and other narrow-therapeutic-range drugs need a specific composition and monitoring review, rather than an explanation based on unproven universal “rejection through immune stimulation”. A historical phenelzine-combination report also deserves attention, but a single case does not establish the same risk frequency across every antidepressant.

| Situation | What actually needs consideration |
|---|---|
| Warfarin or another narrow-therapeutic-range medicine | Species, product and possible interactions; coordination and clinician-prescribed monitoring |
| Insulin or a medicine carrying hypoglycaemia risk | Possible glucose changes; observation without independently lowering medication doses |
| Psychotropic medicines, especially complex combinations | Clinical condition, sleep and interaction reports; do not replace therapy or automatically prescribe the combination |
| Transplantation, complex immunosuppression or active autoimmune disease | Individual disease and medication assessment; neither “safe for everyone” nor “forbidden for everyone” is established |
| Pregnancy, lactation or childhood | Insufficient evidence for independent use |
| Rash, substantial insomnia, palpitations or deterioration | Stop self-experimentation and assess the cause; do not mask a reaction with another supplement |

For someone prone to insomnia, dosing time can be discussed in relation to symptoms and lifestyle, but a strict “not after 5 pm because of melatonin” rule is not established. Historical long-term-misuse descriptions do not prove obligatory tachyphylaxis after two or three months. Arbitrary cycles and “receptor resets” should therefore not be presented as proven protocols. Severe uncontrolled hypertension prioritises medical assessment and treatment, not selecting a stimulating extract; a particular Rg1 pressor mechanism cannot be assumed for every case.

## How to interpret a neuroplasticity promise

Ginseng offers a substantive model of how plant chemistry, microbiota and cell biology meet in one research field. It includes testable pathways: glycoside hydrolysis, metabolite transport, glutamatergic regulation, BDNF/TrkB and microglial responses. It also has boundaries: different molecules may produce opposing receptor effects, different preparations incomparable exposure, and a positive marker may not improve a patient’s life.

For professionals, this knowledge helps formulate a more precise question about a product and a study. Identify the material, the system, the measured outcome and its relevance to an individual’s aim. This sequence preserves interest in mechanisms without turning laboratory neuroplasticity into a promise of universal treatment, “brain rejuvenation” or prevention of every cognitive disorder.

## FAQ

### How does Asian ginseng differ from American ginseng and notoginseng?

They are different Panax species with different compositions and studied preparations. An American-ginseng or Xuesaitong result cannot automatically be attributed to Panax ginseng root.

### Is red or fermented ginseng necessarily more effective?

Processing changes the chemical profile and may greatly increase particular metabolites’ plasma exposure. Superiority for memory, fatigue or disease treatment requires a clinical outcome for that specific product.

### Can a probiotic enhance the effect?

Microbial ginsenoside conversion is strain-specific. Fermentation studies do not prove that any probiotic increases a patient’s CK or improves clinical effects.

### Is new-neuron formation proven in people taking ginseng?

No. Rg1 model findings and human-tissue evidence supporting adult neurogenesis are separate evidence lines. MRI volume is not a count of new neurons either.

### Does CK act like a benzodiazepine?

That generalisation is incorrect. CK inhibited GABA_A currents in a recombinant system; other models give a more complex profile. Flumazenil behaviour experiments do not establish a universal binding site or absence of tolerance.

### Does ginseng treat chronic fatigue or dementia?

Clinical findings are limited to particular preparations and outcomes. The idiopathic-fatigue trial’s overall primary endpoint was not statistically significant; MCI signals do not prove dementia prevention. Diagnosis and accepted treatment must not be replaced.

### Is there a proven cycle and break schedule?

These studies establish neither a universal five-days-on/two-days-off regimen, obligatory receptor resets nor a uniform course length. Decisions depend on product, purpose, tolerability and clinical context.

### What matters most for selection and safety?

Exact species, plant part, formulation and composition, batch quality, clinical purpose and concurrent medicines. Evidence is insufficient in pregnancy, lactation and childhood; narrow-therapeutic-range drug combinations require coordination.

## Sources

- [Flora of China: Panax ginseng C. A. Meyer](https://www.efloras.org/florataxon.aspx?flora_id=3&taxon_id=200015246)
- [Kew Plants of the World Online: Panax ginseng C.A.Mey.](https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:91472-1/general-information)
- [Chen et al. — Crystal structure and physical stability of ginsenoside compound-K solvates](https://doi.org/10.1039/C9CE00965E)
- [PubChem: Ginsenoside K, CID 9852086](https://pubchem.ncbi.nlm.nih.gov/compound/Ginsenoside-K)
- [Baek et al. — Ginsenoside Rs3, a genuine dammarane-glycoside from Korean red ginseng](https://doi.org/10.1007/BF02976158)
- [Vo et al. — Kinetic study for the optimization of ginsenoside Rg3 production by heat treatment of ginsenoside Rb1](https://doi.org/10.1016/j.jgr.2015.02.003)
- [Remarkable impact of steam temperature on ginsenosides transformation from fresh ginseng to red ginseng](https://pmc.ncbi.nlm.nih.gov/articles/PMC6026370/)
- [Biotransformation of ginsenoside Rb1 via the gypenoside pathway by human gut bacteria](https://pmc.ncbi.nlm.nih.gov/articles/PMC4175505/)
- [Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora](https://pubmed.ncbi.nlm.nih.gov/22584255/)
- [Wang et al. — Brain Transport Profiles of Ginsenoside Rb1 by Glucose Transporter 1: In Vitro and in Vivo](https://doi.org/10.3389/fphar.2018.00398)
- [Ban et al. — Pharmacokinetics of Ginsenoside Compound K From a Compound K Fermentation Product, CK-30, and From Red Ginseng Extract in Healthy Korean Subjects](https://pubmed.ncbi.nlm.nih.gov/33884767/)
- [Shin et al. — Pharmacokinetic Comparison of Ginsenosides between Fermented and Non-Fermented Red Ginseng in Healthy Volunteers](https://pubmed.ncbi.nlm.nih.gov/36559300/)
- [Jiang et al. — Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus](https://pubmed.ncbi.nlm.nih.gov/22335772/)
- [Sun et al. — Ginsenoside Rg1 Promotes the Survival, Proliferation, and Differentiation of Senescent Neural Stem Cells Induced by D-galactose](https://doi.org/10.62641/aep.v53i1.1812)
- [Ginsenoside Rg1 promotes neurite growth of retinal ganglion cells through cAMP/PKA/CREB pathways](https://pmc.ncbi.nlm.nih.gov/articles/PMC10920000/)
- [Li et al. — Ginsenoside Rg1 ameliorates hippocampal long-term potentiation and memory in an Alzheimer’s disease model](https://doi.org/10.3892/mmr.2016.5103)
- [Mutation at the TrkB PLCγ-docking site affects hippocampal LTP and associative learning in conscious mice](https://pmc.ncbi.nlm.nih.gov/articles/PMC1838546/)
- [Disouky et al. — Human hippocampal neurogenesis in adulthood, ageing and Alzheimer’s disease](https://doi.org/10.1038/s41586-026-10169-4)
- [Kim et al. — Ginsenoside Rg3 antagonizes NMDA receptors through a glycine modulatory site in rat cultured hippocampal neurons](https://pubmed.ncbi.nlm.nih.gov/15369768/)
- [Lee et al. — 20(S)-ginsenoside Rh2, a newly identified active ingredient of ginseng, inhibits NMDA receptors in cultured rat hippocampal neurons](https://doi.org/10.1016/j.ejphar.2006.02.038)
- [Zhang et al. — Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson’s disease](https://pubmed.ncbi.nlm.nih.gov/29241654/)
- [Zhang et al. — Ginsenoside Rd promotes glutamate clearance by up-regulating glial glutamate transporter GLT-1 via PI3K/AKT and ERK1/2 pathways](https://pubmed.ncbi.nlm.nih.gov/24376419/)
- [Lee et al. — Effects of Ginsenoside Metabolites on GABAA Receptor-Mediated Ion Currents](https://doi.org/10.5142/jgr.2012.36.1.55)
- [The Effects of Ginsenoside Compound K Against Epilepsy by Enhancing the γ-Aminobutyric Acid Signaling Pathway](https://pubmed.ncbi.nlm.nih.gov/30254585/)
- [Rg1 improves LPS-induced Parkinsonian symptoms in mice via inhibition of NF-κB signaling and modulation of M1/M2 polarization](https://pmc.ncbi.nlm.nih.gov/articles/PMC7468333/)
- [Ginsenoside Rg1 Exerts Anti-inflammatory Effects via G Protein-Coupled Estrogen Receptor in Lipopolysaccharide-Induced Microglia Activation](https://pubmed.ncbi.nlm.nih.gov/31787867/)
- [Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—the key step of inflammation](https://pubmed.ncbi.nlm.nih.gov/21600888/)
- [Yang et al. — Ginsenoside Rg3 promotes beta-amyloid peptide degradation by enhancing gene expression of neprilysin](https://pubmed.ncbi.nlm.nih.gov/19222911/)
- [Joo and Lee — Potential effects of microglial activation induced by ginsenoside Rg3 in rat primary culture: enhancement of type A Macrophage Scavenger Receptor expression](https://pubmed.ncbi.nlm.nih.gov/16276974/)
- [Jang et al. — An Aβ42 uptake and degradation via Rg3 requires an activation of caveolin, clathrin and Aβ-degrading enzymes in microglia](https://pubmed.ncbi.nlm.nih.gov/25848967/)
- [Lee et al. — Ginsenoside-Rg1, one of the major active molecules from Panax ginseng, is a functional ligand of glucocorticoid receptor](https://pubmed.ncbi.nlm.nih.gov/9406859/)
- [Panossian et al. — Adaptogens exert a stress-protective effect by modulation of expression of molecular chaperones](https://pubmed.ncbi.nlm.nih.gov/19188053/)
- [Saleh et al. — Negative regulation of the Apaf-1 apoptosome by Hsp70](https://www.nature.com/articles/ncb0800_476)
- [Beere et al. — Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome](https://pubmed.ncbi.nlm.nih.gov/10934466/)
- [Reay et al. — Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mental activity](https://pubmed.ncbi.nlm.nih.gov/15982990/)
- [Kennedy et al. — Dose dependent changes in cognitive performance and mood following acute administration of Ginseng to healthy young volunteers](https://pubmed.ncbi.nlm.nih.gov/11842896/)
- [Reay et al. — Panax ginseng (G115) improves aspects of working memory performance and subjective ratings of calmness in healthy young adults](https://pubmed.ncbi.nlm.nih.gov/20737519/)
- [Kim et al. — Antifatigue effects of Panax ginseng C.A. Meyer: a randomised, double-blind, placebo-controlled trial](https://pubmed.ncbi.nlm.nih.gov/23613825/)
- [Wu et al. — Efficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China: A Randomized Clinical Trial](https://pubmed.ncbi.nlm.nih.gov/37338907/)
- [Park et al. — Cognition enhancing effect of panax ginseng in Korean volunteers with mild cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial](https://doi.org/10.12793/tcp.2019.27.3.92)
- [Namgung et al. — Effects of Korean red ginseng on human gray matter volume and cognitive function: A voxel-based morphometry study](https://pubmed.ncbi.nlm.nih.gov/33217050/)
- [EMA/HMPC — Ginseng radix: European assessment and traditional medicinal use](https://www.ema.europa.eu/en/medicines/herbal/ginseng-radix)
- [Yuan et al. — Brief communication: American ginseng reduces warfarin’s effect in healthy patients: a randomized, controlled trial](https://pubmed.ncbi.nlm.nih.gov/15238367/)
- [Interaction between warfarin and Panax ginseng in ischemic stroke patients](https://pubmed.ncbi.nlm.nih.gov/18637764/)
- [Penzak et al. — Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (Pgp) activity in healthy subjects](https://pmc.ncbi.nlm.nih.gov/articles/PMC3523324/)
- [Jones and Runikis — Interaction of ginseng with phenelzine](https://pubmed.ncbi.nlm.nih.gov/3597812/)
- [Chan et al. — An in-vitro study of ginsenoside Rb1-induced teratogenicity using a whole rat embryo culture model](https://pubmed.ncbi.nlm.nih.gov/14507839/)
- [Siegel — Ginseng abuse syndrome. Problems with the panacea](https://pubmed.ncbi.nlm.nih.gov/430716/)
- [Kim — Gut microbiota-mediated pharmacokinetics of ginseng saponins](https://pubmed.ncbi.nlm.nih.gov/29983606/)
- [Lee and Rhee — Effects of ginseng on stress-related depression, anxiety, and the hypothalamic-pituitary-adrenal axis](https://doi.org/10.1016/j.jgr.2017.01.010)
- [Panossian and Wikman — Effects of Adaptogens on the Central Nervous System and the Molecular Mechanisms Associated with Their Stress-Protective Activity](https://doi.org/10.3390/ph3010188)
- [Radad et al. — Use of ginseng in medicine with emphasis on neurodegenerative disorders](https://doi.org/10.1254/jphs.CR0050010)
- [Geng et al. — Ginseng for cognition](https://doi.org/10.1002/14651858.CD007769.pub2)
- [Tan et al. — Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus](https://pubmed.ncbi.nlm.nih.gov/28478490/)